<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03871322</url>
  </required_header>
  <id_info>
    <org_study_id>MUBialystok1</org_study_id>
    <nct_id>NCT03871322</nct_id>
  </id_info>
  <brief_title>The Vitamin K2 and D3 Intervention Trial in Children and Adolescents With the Low-energy Fractures</brief_title>
  <official_title>Rationale and Design of the Vitamin K2 and Vitamin D3 Intervention Trial in Children and Adolescents With the Low-energy Bone Fractures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Bialystok</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lomza State University of Applied Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>International Science &amp; Health Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>American Medical Holdings Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Bialystok</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      a prospective, three- month, randomized, double-blind, placebo-controlled, intervention trial
      (RDBPC), investigating the effect of vitamin K2 (menaquinone-7) and vitamin D3 on the healing
      process of low-energy bone fractures in children and adolescents
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At the admission of patients to the orthopedic outpatient clinic, presence of low- energy
      fractures will be established based on the anamnesis, physical examination and radiological
      evaluation. Tests to obtain the baseline blood levels of vitamin D3 will be performed, and
      only children with vitamin D3 levels lower than 30ng/ml in the blood will be included in the
      study. The selected population will then be randomly assigned by an independent investigator
      to the three study groups, receiving daily for three months identical- looking soft gel
      capsules (1 capsule/patient/day) containing supplements of vitamin D3 2,000 IU, 90 mcg of
      vitamin K2 as menaquinone-7 combined with 2,000 IU D3, and olive oil-containing placebo
      capsules respectively. During the 3-month follow-up visits to the outpatient orthopedic
      clinic, the pediatric orthopedist will examine the patient, evaluate the X-ray, and determine
      the progress in bone union and the range of joint motion. The patients will visit the clinic
      on weeks 1,2,4,6,8, and 12. The compliance taking the supplements will be assessed by
      registering a pill count returned by a patient during the scheduled visit. The blood samples
      will be collected upon admission to the study, day 0, and after the 3-month regimen. The
      blood samples will be collected for evaluation of bone turnover markers and the status of
      vitamin K and vitamin D3. The primary evaluation endpoints will include: the dynamics of
      fracture healing, changes in levels of osteocalcin, and vitamin K and vitamin D3 levels
      against the placebo group. The bone fracture healing milestones will be based on bone union
      defined as the absence of pain and the presence of bridging callus in three of the four
      cortices seen on the front rear projection and lateral radiographic views of the bone.
      Delayed union is defined as incomplete consolidation at 90 Days
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">January 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 24, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>a prospective, three- month, randomized, double-blind, placebo-controlled, intervention trial (RDBPC),</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>double-blind, placebo, same looking capsules</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>time to bone union</measure>
    <time_frame>3 months</time_frame>
    <description>The bone fracture healing milestones will be based on bone union defined as the absence of pain and the presence of bridging callus in three of the four cortices seen on the AnteroPosteral and lateral radiographs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vitamin D concentration changes</measure>
    <time_frame>3 months</time_frame>
    <description>changes in vitamin D serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin K2 concentration changes</measure>
    <time_frame>3 months</time_frame>
    <description>changes in vitamin K2 serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in bone markers concentration</measure>
    <time_frame>3 months</time_frame>
    <description>Changes in bone-specific alkaline phosphatase (BALP), N-terminal telopeptide (NTX)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Fracture Healing</condition>
  <condition>Vitamin D3</condition>
  <condition>Deficiency of Vitamin K2</condition>
  <arm_group>
    <arm_group_label>Vitamin D group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>vitamin D supplementation - time to fracture healing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D and K2 group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin D and K 2 supplementation - time of fracture healing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo - time to fracture healing</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D and K2 supplementation</intervention_name>
    <description>if supplementation of vitamin D and K2 changes the time to fracture healing</description>
    <arm_group_label>Vitamin D and K2 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D supplementation</intervention_name>
    <description>if supplementation of vitamin D alone changes the time to fracture healing</description>
    <arm_group_label>Vitamin D group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo control group</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &lt; 18 years

          -  Presence of low-energy fracture

          -  Vitamin D serum level &lt;30ng/ml

        Exclusion Criteria:

          -  Age &gt; 18 years

          -  Lack of low-energy bone fracture

          -  Oral anticoagulants treatments, which interfere with vitamin K cycle

          -  Current supplementation with vitamin vitamins K2 or vitamin D3

          -  Osteogenesis imperfecta and other bone diseases

          -  Vitamin D concentration &gt; 30ng/ml
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janusz Popko, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Faculty of Health Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michał Karpinski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pediatric Orthopedics and Traumatology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tomasz Guszczyn, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Pediatric Orthopedics and Traumatology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sylwia Chojnowska, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Faculty of Health Sciences Lomza</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Katarzyna Maresz, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>International Science &amp;amp;Health Foundation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vladimir Badmaev</last_name>
    <role>Study Director</role>
    <affiliation>American Medical Holdings Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michał Karpiński, MD</last_name>
    <phone>692224714</phone>
    <phone_ext>48</phone_ext>
    <email>gufkarp@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Pediatric Orthopedics and Traumatology Medical University of Bialystok</name>
      <address>
        <city>Bialystok</city>
        <zip>15-274</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michal Karpinski, MD</last_name>
      <phone>692224714</phone>
      <phone_ext>+48</phone_ext>
      <email>gufkarp@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Janusz Popko, MD, PhD</last_name>
      <phone>857450895</phone>
      <phone_ext>+48</phone_ext>
      <email>jpopko@umb.edu.pl</email>
    </contact_backup>
    <investigator>
      <last_name>Michal Karpinski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Janusz Popko, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vladimir Badmaev, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tomasz Guszczyn, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katarzyna Maresz, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 7, 2019</study_first_submitted>
  <study_first_submitted_qc>March 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2019</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vitamin D</keyword>
  <keyword>vitamin K2</keyword>
  <keyword>low-energy fractures</keyword>
  <keyword>fracture healing</keyword>
  <keyword>children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin K Deficiency</mesh_term>
    <mesh_term>Fractures, Bone</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

